Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2021.07.021
Abstract: BACKGROUND & AIMS Cases of acute liver injury (ALI) have been reported among chronic hepatitis C virus-infected initiators of protease inhibitor (PI)-based direct-acting antiviral (DAA) regimens, predominately with decompensated cirrhosis in whom these therapies are… read more here.
Keywords: protease inhibitor; risk; inhibitor based; dysfunction ... See more keywords
Similar plasma lipidomic profile in people living with HIV treated with a darunavir-based or an integrase inhibitor-based antiretroviral therapy
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-53761-7
Abstract: Cardiovascular disease is an important cause of morbidity and mortality in people living with HIV (PLWH), who commonly experience lipid disturbances. The aim of this study was to determine whether the plasma lipidomic profile differs… read more here.
Keywords: based art; lipidomic profile; inhibitor based; darunavir based ... See more keywords
Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01902-19
Abstract: HIV persistence despite therapy contributes to chronic immune activation and inflammation, increasing the risk of aging-associated events in HIV-infected individuals. We sought here to better understand the complex link between clinical and treatment features and… read more here.
Keywords: therapy; inhibitor based; treatment; viremia ... See more keywords
Abstract P2-05-16: Interrogating serum thymidine kinase activity with CDK4/6 inhibitor-based therapies: real-world experience in the metastatic and adjuvant setting
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p2-05-16
Abstract: Background: CDK4/6 inhibitors have become widely deployed in the treatment of HR+/HER2- breast cancer. In the metastatic setting, a number of different CDK4/6 inhibitors are approved in combination with endocrine therapy and lead to a… read more here.
Keywords: tka levels; inhibitor based; cdk4 inhibitor; cdk4 ... See more keywords
The safety and efficacy of anti-PD-1 inhibitor-based combinational therapy in non-small cell lung cancer patients with oncogenic alterations
Sign Up to like & getrecommendations! Published in 2024 at "Translational Cancer Research"
DOI: 10.21037/tcr-23-1092
Abstract: Background The anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunotherapy has been extensively used in patients with non-small cell lung cancer (NSCLC) in which the tumors are negative for oncogenic alterations. However,… read more here.
Keywords: therapy; anti inhibitor; inhibitor based; combinational therapy ... See more keywords
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
Sign Up to like & getrecommendations! Published in 2022 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s358976
Abstract: Background The primary objective of this study was to estimate the proportion of people living with HIV (PLWH) who switched from a non-protease inhibitor (PI)-based regimen [integrase strand transfer inhibitor (InSTI)-based or non-nucleoside reverse transcriptase… read more here.
Keywords: taf; inhibitor based; non protease; inhibitor ... See more keywords
Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1171671
Abstract: Purpose In recent years, a number of clinical trials have shown that programmed death 1 (PD-1) inhibitors offer significant survival benefits in patients with esophageal squamous cell carcinoma (ESCC). We conducted a meta-analysis to explore… read more here.
Keywords: inhibitor based; based therapy; meta analysis; inhibitor ... See more keywords
Effectiveness of PD-1 inhibitor-based first-line therapy in Chinese patients with metastatic gastric cancer: a retrospective real-world study
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2024.1370860
Abstract: Objective Programmed cell death protein-1 (PD-1) inhibitor-based therapy has demonstrated promising results in metastatic gastric cancer (MGC). However, the previous researches are mostly clinical trials and have reached various conclusions. Our objective is to investigate… read more here.
Keywords: inhibitor based; metastatic gastric; therapy; first line ... See more keywords
Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Public Health"
DOI: 10.3389/fpubh.2018.00063
Abstract: Background Assessment of virological outcomes among HIV-infected patients receiving protease (PR) inhibitor-based second-line regimen are uncommon in Cambodia. The objective of this study is to assess the virological effectiveness of this regimen as well as… read more here.
Keywords: inhibitor based; line; line regimen; study ... See more keywords